Seminars in Hematology
Volume 46, Issue 3 , Pages 289-312 , July 2009

Management of Infections Complicating Allogeneic Hematopoietic Stem Cell Transplantation

References 

  1. Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic stem cell transplantation for high-risk acute leukemia. Hematologica. 2002;87:52–58
  2. Junghanass C, Marr KA. Infectious risks and outcomes after stem cell transplantation: are myeloablative transplants changing the picture?. Current Opin Infect Dis. 2002;15:347–353
  3. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood of bone marrow from unrelated donors. N Engl J Med. 2004;351:2265–2275
  4. Takahashi S. Leukemia: cord blood for allogeneic stem cell transplantation. Curr Opin Oncol. 2007;19:667–672
  5. Richard S, Schuster MW. Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002;1:103–109
  6. Boeckh M, Garret WG, Papanicolau G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges and future strategies. Biol Blood Marrow Transplant. 2003;9:543–558
  7. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpes virus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932–940
  8. Deej HJ, Meyers JD, Storb R, Graham TC, Weiden PL. The effect of trimethoprim-sulfamethoxazole on hematological recovery after total body irradiation and autologous marrow infusion in dogs. Transplantation. 1979;28:243–246
  9. Jancel T, Penzak P. Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia. Semin Hematol. 2009;(current issue)
  10. Storek J, Witherspoon RP. Immunologic reconstitution after hematopoietic stem cell transplantation. In:  Atkinson K editors. Clinical bone marrow and blood stem cell transplantation. 2nd ed.. Cambridge, UK: Cambridge University Press; 2000;p. 111–146
  11. Tayebi H, Tiberghien P, Ferrand C, Lienard A, Duperrier A, Cahn JY, et al. Allogeneic peripheral blood stem cell transplantation results in less alteration of early T cell compartment homeostasis than bone marrow transplantation. Bone Marrow Transplant. 2001;27:167–175
  12. Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant. 1995;16:413–425
  13. Ashihara E, Shimazaki C, Yamagata N, Hirata T, Okawa K, Oku N, et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis. Bone Marrow Transplant. 1994;13:377–381
  14. Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after cytotoxic chemotherapy. Blood. 1989;73:1351–1358
  15. Atkinson K. Reconstruction of the haematopoietic and immune systems after marrow transplantation. Bone Marrow Transplant. 1990;5:202–226
  16. Noel DR, Witherspoon RP, Storb R, Atkinson K, Doney K, Mickelson EM, et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? (An observation on long-term survivors). Blood. 1978;51:1087–1105
  17. Quinnan GV, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med. 1982;307:7–13
  18. Meyers JD, Flournoy N, Thomas ED. Cell mediated immunity to varicella-zoster virus after allogeneic marrow transplant. J Infect Dis. 1980;141:479–487
  19. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis. 1980;142:338–346
  20. Witherspoon RP, Deeg HJ, Lum LG, Ochs HD, Hansen JA, Thomas ED, et al. Immunologic recovery in human marrow graft recipients given cyclosporine or methotrexate for the prevention of graft-versus-host disease. Transplantation. 1984;37:456–461
  21. Witherspoon RP, Lum LG, Storb R, Thomas ED. In vitro regulation of immunoglobulin synthesis after human marrow transplantation (Deficient T and non-T lymphocyte function within 3-4 months of allogeneic, syngeneic, or autologous marrow grafting for hematopoietic malignancy). Blood. 1982;59:844–850
  22. Atkinson K, Munro V, Vasak E, Biggs JC. Mononuclear cell populations in the skin defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. Br J Dermatol. 1986;114:145–160
  23. Small TN, Robinson WH, Miklos DB. B cells and transplantation: an educational resource. Biol Blood Marrow Transplant. 2009;15:104–113
  24. Raaphorst FM. Reconstitution of the B cell repertoire after bone marrow transplantation does not recapitulate human fetal development. Bone Marrow Transplant. 1999;24:1267–1272
  25. Winston DJ, Schiffman G, Wang DC, Feig SA, Lin CH, Marso EL, et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med. 1979;91:835–841
  26. Norlin A-C, Sairafi D, Mattsson J, Ljungman P, Ringden O, Remberger M. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant. 2008;41:267–273
  27. Storek J, Viganego F, Dawson MA, Herremans MMPT, Boeckh M, Flowers MED, et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood. 2003;101:3319–3324
  28. Dykewicz CA Centers for Disease Control and Prevention (US) Infectious Diseases Society of America American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–144
  29. Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 2005;35:737–746
  30. Winston DJ, Territo MC, Ho WG, Miller MJ, Gale RP, Golde DW. Alveolar macrophage dysfunction in human bone marrow transplant recipients. Am J Med. 1982;73:859–866
  31. Bentel J, Atkinson K. Cytokine activity after human bone marrow transplantation: production of macrophage procoagulant activity and the T lymphokine regulating its production. Br J Haematol. 1988;69:181–187
  32. Nachbaur D, Kircher B, Eisendle K, Latzer K, Haun M, Gastl G. Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic stem cell transplantation. Br J Haematol. 2003;123:119–126
  33. Penack O, Fischer L, Stroux A, Gentilini C, Nogal A, Muessig A, et al. A novel method to quantify and characterize leukemia-reactive natural killer cells in patients undergoing allogeneic stem cell transplantation following conventional or reduced dose conditioning. Int J Hematol. 2007;85:326–332
  34. Kim DH, Sohn SK, Lee NY, Baek JH, Kim JG, Won DI, et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Haematol. 2005;75:299–308
  35. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98:3192–3204
  36. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year survival in recipients of unrelated donor bone marrow (T-Cell Depletion Trial): a multi-center, randomized phase II-III trial. Lancet. 2005;366:733–741
  37. Novitzky N, Rubinstein R, Hallett JM, du Toit CE, Thomas VL. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myelogenous leukemia: a therapeutic strategy. Transplantation. 2000;69:1358–1363
  38. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001;19:3685–3691
  39. Junghanss C, Marr KA. Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?. Curr Opin Infect Dis. 2002;15:347–353
  40. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Ponce-De-León S, Cantú-Rodriguez OG, Jaime-Pérez JC. No cytomegalovirus-related deaths after non-ablative stem cell allografts. Hematology. 2002;7:95–99
  41. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357–4363
  42. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559–566
  43. Samonis G, Kontonyiannis DP. Infectious complications of purine analog therapy. Curr Opin Infect Dis. 2001;14:409–413
  44. Tam CS, Wolf MM, Januszewicz EH, Grigg AP, Prince HM, Westerman D, et al. A new model for predicting infectious complications during fludarabine based combination chemotherapy among patients with indolent lymphoma. Cancer. 2004;101:2042–2049
  45. Greinix HT, Fae I, Schneider B, Rosenmayr A, Mittershiffthaler A, Pelzmann B, et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant. 2005;35:57–62
  46. Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant. 2006;38:83–93
  47. Eurocord, European Blood and Marrow Transplant GroupRocha V, Gluckman E. Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant. 2006;12(Suppl 1):34–41
  48. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic survival and engraftment in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815–1822
  49. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105:1343–1347
  50. Viollier R, Socié G, Tichelli A, Bacigalupo A, Korthof ET, Marsh J, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant. 2008;41:45–50
  51. US Department of Health and Human Services Advisory Council on Blood Stem Cell Transplantation (ACBSCT) January 28-29, 2008. http://bloodcell.transplant.hrsa.gov/ABOUT/Advisory_Council/Meetings/Notes/DOCS/ACBSCT_Summary_Notes_Jan2008.pdfAccessed February 20, 2009.
  52. Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. Blood. 2003;101:4233–4244
  53. Ljungman P, de la Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P, et al. European Conference on Infections in Leukemia (Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT). Bone Marrow Transplant. 2008;42:227–240
  54. Walker CM, van Burik JH, De For TE, Weisdorf DJ. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant. 2007;13:1106–1115
  55. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003;102:4255–4260
  56. Chemaly RF, Gosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85:278–287
  57. Martino R, Porras RP, Rabella N, Williams JV, Ramila E, Margall N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11:781–796
  58. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28:479–484
  59. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003;32:1085–1088
  60. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8:191–199
  61. Sirvent-von Bueltzingsloewen A, Marty P, Rosenthal E, Delaunay P, Allieri-Rosenthal A, Gratecos N, et al. Visceral leishmaniasis: a new opportunistic infection in hematopoietic stem-cell-transplanted patients. Bone Marrow Transplant. 2004;33:667–668
  62. Sepkowitz KA. Risks and epidemiology of infections after allogeneic hematopoietic stem cell transplantation. In:  Bowden RA,  Ljungman P,  Paya CV editor. Transplant infections. 2nd ed.. Philadelphia: Lippincott Williams & Wilkins; 2003;p. 31–38
  63. Deeg HJ, Bowden RA. Introduction to hematopoietic stem cell transplantation. In:  Bowden RA,  Ljungman P,  Paya CV editor. Transplant infections. 2nd ed.. Philadelphia: Lippincott Williams & Wilkins; 2003;p. 3–16
  64. Engelhard D, Geller N, Paterson DL. Gram-positive and gram-negative infections after hematopoietic stem cell or solid organ transplantation. In:  Bowden RA,  Ljungman P,  Paya CV editor. Transplant infections. 2nd ed.. Philadelphia: Lippincott Williams & Wilkins; 2003;p. 225–249
  65. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–1552
  66. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–851
  67. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow up of a randomized, placebo controlled trial. Blood. 2000;96:2055–2061
  68. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459–1466
  69. Ribaud P, Chastang C, Latgé JP, Baffroy-Lafitte L, Parquet N, Devergie A, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis. 1999;28:322–330
  70. Marr KA, Carter RA, Boeck M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–4366
  71. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–917
  72. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34:115–121
  73. Hiemenz JW, Groll AH, Walsh TJ. Infections caused by rare fungi after hematopoietic stem cell or solid organ transplantation. In:  Bowden RA,  Ljungman P,  Paya CV editor. Transplant infections. 2nd ed.. Philadelphia: Lippincott Williams & Wilkins; 2003;p. 509–523
  74. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Haung ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants; importance of viral load and T cell immunity. Blood. 2003;101:407–414
  75. Machado CM, Dulley FL, Vilas Boas LS, Castelli JB, Macedo MCA, Silva RL, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000;26:413–417
  76. Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979–3986
  77. Bjorklund A, Ashcan J, Labopin M, Remberger M, Ringden O, Winiarski J, et al. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;40:1055–1062
  78. Robin M, Porcher R, De Castro Araujo R, de Latour RP, Devergie A, Rocha V, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant. 2007;13:1304–1312
  79. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, et al. Management of HSV, VZV, and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2008;Dec 1. Epub ahead of print. doi: 10.1038/bmt.2008.386
  80. Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematpoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7:11–17
  81. Reilly AF, Lange BJ. Infections with viridians group streptococci in children with cancer. Pediatr Blood Cancer. 2007;49:774–780
  82. Gassas A, Grant R, Richardson S, Dupuis LL, Doyle J, Allen U, et al. Predictors of viridians streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol. 2004;22:1222–1227
  83. Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridians group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis. 2005;24:832–838
  84. Toro JJ, Morales M, Loberiza F, Ochoa-Bayona JL, Freytes CO. Patterns of use of vascular access devices in patients undergoing hematopoietic stem cell transplantation: results of an international survey. Support Care Cancer. 2007;15:1375–1383
  85. Kim DH, Bae NY, Sung WJ, Kim JG, Kim SW, Baek JH, et al. Hickman catheter site infections after allogeneic stem cell transplantation: a single-center experience. Transplant Proc. 2004;36:1579-3
  86. Kaufman LJ, Clark TW, Roberts DA, Freiman DB, Shlansky-Goldberg RD, Patel AA, et al. Do simultaneous bilateral tunneled infusion catheters in patients undergoing bone marrow transplantation increase catheter-related complications?. J Vasc Interv Radiol. 2004;15:57–61
  87. Frere P, Hermanne JP, Debouge MH, Fillet G, Beguin Y. Changing patterns of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2002;29:589–594
  88. Lau SK, Woo PL, Leung KW, Yuen KY. Emergence of cotrimoxazole- and quinolone resistant Campylobacter infections in bone marrow transplant recipients. Eur J Microbiol Infect Dis. 2002;21:127–129
  89. Craig M, Crumpston AP, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG. The clinical impact of antimicrobial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant. 2007;39:477–482
  90. Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston PB, Patel R. Vancomycin resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41:385–392
  91. Dibo I, Pillai SK, Gold HS, Baer HR, Wetzler M, Slack JL, et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol. 2004;42:1843–1845
  92. Green MR, Anasetti C, Sandin RL, Rolfe NE, Greene JN. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract. 2006;12:179–181
  93. Kontoyiannis DP, Lewis RE, Marr K. The burden of bacterial and viral infections in hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2009;15:128–133
  94. Tam VH, Chang KT, LaRocco MT, Schilling AN, McCauley SK, Poole K, et al. Prevalence, mechanisms, and risk factors of carbapenem resistance in blood stream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007;58:309–314
  95. Mena A, Plasencia V, Garcia L, Hidalgo O, Ayestaran JI, Alberti S, et al. Charaterization of a large outbreak by CTX-M-1 producing i and mechanisms leading to in vivo carbapenem resistance development. J Clin Microbiol. 2006;44:2831–2837
  96. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii; mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–836
  97. Pournaras S, Iosifidis E, Roilides E. Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol. 2009;(current issue)
  98. Kumashi P, Girgawy E, Tarrand JJ, Rolston KV, Raad II, Safdar A. Streptococcus pneumonia bacteremia in patients with cancer: disease characteristics in the era of escalating drug resistance. Medicine (Baltimore). 2005;84:303–312
  99. Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002;116:475–482
  100. Marr KA, Carter RA, Boeck M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–4366
  101. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34:115–121
  102. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007;40:451–456
  103. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematological malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425–429
  104. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–653
  105. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006;20:581–607
  106. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment of recipients of hematopoietic stem cell transplants. N Engl J Med. 2004;350:950–952
  107. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, et al. Zygomycosis in a tertiary-care center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–1360
  108. Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol. 2009;(current issue)
  109. Wade JC. Viral infections in patients with hematological malignancies. Hematology [American Society of Hematology Education Program Book]. 2006;368–374
  110. Boeckh M. The challenge of respiratory virus infections in hematopoietic stem cell transplant recipients. Br J Haematol. 2008;143:455–467
  111. Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L, Morrow R, et al. Respiratory virus infection among hematopoietic transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110:1681–1688
  112. Anaissie EJ, Mahfouz TH, Aslan T, Pouli A, Desikan R, Fassas A, et al. The natural history of respiratory synctial virus infection in cancer and transplant patients: implications for management. Blood. 2004;103:1611–1617
  113. Giraud G, Priftakis P, Bogdanovic G, Remberger M, Dudrulle M, Hau A, et al. BK-viruria and haemorrhagic cystitis are more frequent in allogeneic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant. 2008;41:737–742
  114. Giraud G, Bogdanovic G, Priftakis P, Remberger M, Svahn BM, Barkholt L, et al. The incidence of hemorrhagic cystits and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica. 2006;91:401–404
  115. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008;21:704–715
  116. Robin M, Marque-Juillet S, Scieux C, Peffault de Latour R, Ferry C, Rocha V, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica. 2007;92:1254–1257
  117. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72:520–529
  118. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Hematologica. 2006;91:1059–1067
  119. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874–2880
  120. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis. 2000;181:2055–2058
  121. Chen Y, Scieux C, Garrait V, Socie G, Rocha V, Molina JM, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis. 2000;31:927–935
  122. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug resistant HSV disease. J Infect Dis. 2007;196:266–270
  123. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR04):1–40
  124. Boeckh MJ, Ljungman P. Cytomegalovirus infection after hematopoietic stem cell transplantation. In:  Bowden RA,  Ljungman P,  Paya CV editor. Transplant Infections. 2nd ed.. Philadelphia: Lippincott Williams & Wilkins; 2003;p. 277–297
  125. Kollmon C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051
  126. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978–1985
  127. Xhaard A, Robin M, Scieux C, de Latour RP, Deplus S, Mazeron MC, et al. Increased incidence of cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation. Transplantation. 2007;83:80–83
  128. Laarson K, Lonnqvist B, Ringden O, Hedquist B, Ljungman P. CMV retintitis after allogeneic bone marrow transplantation: a report of five cases. Transpl Infect Dis. 2002;4:75–79
  129. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:214–219
  130. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971–1979
  131. Reed EC, Wolford JL, Kopecky KJ, Lilleby KE, Dandliker PS, Todaro JL, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients (A randomized placebo-controlled trial). Ann Intern Med. 1990;112:505–510
  132. Ljungman P, Cordonnier C, Einsele H, Bender-Gotze C, Bosi A, Dekkar A, et al. Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT) (Infectious Diseases Working Party of the EBMT). Bone Marrow Transplant. 1998;21:473–476
  133. Meijer E, Slaper-Cortenbach IC, Thijsen SF, Dekkar AW, Verdonck LF. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell deplection technique. Bone Marrow Transplant. 2002;29:335–339
  134. Kinch A, Oberg G, Arvidson J, Linde A, Pauksens K. Post transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic stem cell transplantation after introduction of monitoring viral load by polymerase chain reaction. Scand J Infect Dis. 2007;39:235–244
  135. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Haario H, Ruutu T, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis. 2007;45:1305–1309
  136. Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N, et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003;101:4290–4297
  137. Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconsititution. Clin Infect Dis. 2006;42:1743–1748
  138. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932–940
  139. Ogata M, Kikuchi H, Satou T, Kawano R, Ikewaki J, Kohono K, et al. Human herpes virus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis. 2006;193:68–79
  140. Kamble RT, Clark DA, Leong HN, Heslop HE, Brenner MK, Carrum G. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:563–566
  141. Visser AM, van Doorman GJ, Cornelissen JJ, van den Bent MJ. Severe amnesia due to HHV-6 encephalitis after allogeneic stem cell transplant. Eur Neurol. 2005;54:233–234
  142. Wang LR, Dong LJ, Zhang MJ, Lu DP. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1031–1037
  143. Hentrich M, Oruzio D, Jager G, Schemmer M, Schleuning M, Schiel X, et al. Impact of human herpesvirus-6 after hematopoietic stem cell transplantation. Br J Haematol. 2005;128:66–72
  144. Pohlmann C, Shetelig J, Reuner U, Bornhauser M, Illmer T, Kiani A, et al. Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient. Clin Infect Dis. 2007;44:e118–e120
  145. Ogata M, Satou T, Kawano R, Goto K, Ikewaki J, Kohno K, et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantion: a prospective evaluation. Bone Marrow Transplant. 2008;41:279–285
  146. Boutolleau D, Fernandez C, Andre E, Imbert-Marcille BM, Milpied N, Agut H, et al. Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis. 2003;187:179–186
  147. Ward KN, White RP, Mackinnon S, Hanna M. Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient. Bone Marrow Transplant. 2002;30:983–985
  148. Bruno B, Sorasio R, Barozzi P, Vieira J, Omede P, Giaretta F, et al. Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. Eur J Haematol. 2006;76:342–347
  149. Luppi M, Barozzi P, Rasini V, Torelli G. HHV-8 infection in the transplant setting: a concern only for solid organ transplant patients?. Leuk Lymphoma. 2002;43:517–522
  150. Muller WJ, Levin MJ, Shin YK, Robinson C, Quinones R, Malcolm J, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis. 2005;41:1812–1816
  151. Fanourgiakis P, Georgala A, Vekemans M, Triffet A, De Bruyn JM, Duchateau V, et al. Intravesicular instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis. 2005;40:199–201
  152. Neofytos D, Ojha A, Mookerjee B, Wagner J, Filicko J, Ferber A, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant. 2007;13:74–81
  153. Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant. 2008;41:11–18
  154. Green M, Ljungman P, Michaels MG. Adenovirus, parvovirus B19, papilloma virus, and polyomaviruses after hematopoietic stem cell or solid organ transplantation. In:  Bowden RA,  Ljungman P,  Paya CV editor. Transplant infections. 2nd ed.. Philadelphia: Lippincott Williams & Wilkins; 2003;p. 399–411
  155. Erard V, Storer B, Corey L, Nollkamper J, Huang ML, Limaye A, et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors and association with post engraftment hemorrhagic cystitis. Clin Infect Dis. 2004;39:1861–1865
  156. Bridges B, Donegan S, Badros A. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Am J Hematol. 2006;81:535–537
  157. Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant. 2007;39:783–787
  158. Lekakis LJ, Macrinici V, Baraboutis IG, Mitchell B, Howard DS. BK virus nephropathy after allogeneic transplantation: a case report and literature review. Am J Hematol. 2009;84:243–246
  159. Leung AYH, Chan MTL, Yeun KY, Cheng VCC, Chan KH, Wong CLP, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:528–537
  160. Behre G, Becker M, Christopeit M. BK virus encephalitis in an allogeneic hematopoietic stem cell recipient. Bone Marrow Transplant. 2008;42:499
  161. Englund JA, Boeckh M, Kupyers J, Nichols WG, Hackman RC, Morrow RA, et al. Brief communication:fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144:344–349
  162. Nauseff WN, Maki DG. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med. 1981;304:448–453
  163. Pizzo PA. Do the results justify the expense of protected environments?. In:  Weirnik P editors. Controversies in oncology. New York: John Wiley & Sons; 1982;p. 267–277
  164. Dykewicz CA. Hospital infection control in hematopoietic stem cell transplant recipients. Emerg Infect Dis. 2001;7:263–267
  165. Peterson F, Thornquist M, Buckner C, et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection. 1988;16:188–208
  166. Slavin MA, Grigg AP, Schwarer AP, Szer J, Spencer A, Sainani A, et al. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:157–163
  167. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long term prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med. 2003;138:705–713
  168. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Intraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplantations. Blood. 2004;103:1527–1533
  169. van Burik JH, Ranathanatharathorn V, Stephan DE, Miller CB, Lipton J, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis of invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–1416
  170. Hiemenz J, Cagnoni P, Simpson D, Devine S, Choa N, Keirns J, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole in versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 2005;49:1331–1336
  171. Hamza NS, Ghannoum MA, Lazarus HM. Changes a plenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2004;34:377–389
  172. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. [abstract] Blood. 2007;110:163
  173. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347
  174. De Castro N, Neuville S, Sarfati C, Ribaud P, Derouin F, Gluckman E, et al. Occurrence of Pneumocystis jirovoeci pneumonia after allogeneic stem cell transplantation: a 6 year retrospective study. Bone Marrow Transplant. 2005;36:879–883
  175. Worth LJ, Dooley MJ, Seymour JF, Mileshkin L, Slavin MA, Thursky KA. An analysis of the utilization of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer. 2005;92:867–872
  176. Colby C, McAfee SL, Sackstein R, Finkelstein DM, Fishman JA, Spitzer TR. A prospective randomized trial comparing toxicity and safety of atovaquone following with trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplant. Bone Marrow Transplant. 1999;24:897–902
  177. Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients following dapsone prophylaxis. Clin Infect Dis. 1999;29:1467–1471
  178. Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic transplantation. Transpl Infect Dis. 2002;4:66–74
  179. Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000;6:35–43
  180. Machado CM, Macedo MCA, Medeiros RSS, Massumoto C, Silva ACM, Castella JB, et al. Primary Pneumocysts carinii prophylaxis with aerosolized pentamidine after bone marrow transplantation. Acta Haematol. 1998;99:54–56
  181. Winston DJ, Young JH, Pullarkat V, Papanicoloau GA, Vij R, Vance E, et al. Maribivar prophylaxis for prevention of CMV infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo controlled, dose ranging study. Blood. 2008;111:5403–5410
  182. Boeckh M, Nichols G, Chemaly R, Papanicolaou G, Wingard J, Kirby KA, et al. Prevention of late CMV disease after HCT: a randomized double-blind multicenter trial of valganciclovir (VGCV) prophylaxis versus PCR-guided GCV/VGCV preemptive therapy. Biol Blood Marrow Transplant. 2008;14:30
  183. Hobeika A, Osada T, Serra D, Peplinski S, Hanson K, Tanaka Y, et al. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. Cytotherapy. 2008;10:289–302
  184. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical infection. Blood. 2003;102:3060–3067
  185. Levy JB, Pusey CD. Nephrotoxicity of intravenous immunoglobulin. Q J Med. 2000;93:751–755

PII: S0037-1963(09)00060-2

doi: 10.1053/j.seminhematol.2009.03.005

Seminars in Hematology
Volume 46, Issue 3 , Pages 289-312 , July 2009

Article Tools

* Image Usage & Resolution